Urological disorders occur from the earliest stage of development through the end of life. Many are chronic and affect individual not by shortening survival but by impairing quality of life.
Urology deals with diseases of the male and female urinary tracts (kidneys, ureters, bladder, and urethra). It also deals with the male organs involved in the reproductive system (prostate, seminal vesicles, testis, scrotum, penis) that could affect urinary physiology. Urology is recognized as both a medical and surgical specialty. It is a branch of men’s and women’s health specialties that also include andrology, gynecology and ageing specificities.
The main urological diseases are either benign or malignant. Obstructive benign prostatic hypertrophy (BPH) is a very common condition that occurs in more than 50% of men over the age of 50. Urinary incontinence due to bladder or urethral deterioration occurs in about 17% of people. Lithiasis, or stone diseases, congenital or acquired abnormalities of upper (kidneys and ureters) or lower (bladder and urethra) urinary tracts, are also frequent conditions.
In benign diseases, there is a necessity to research two conditions that affect patients’ quality of life. They are urinary incontinence and the role of inflammation in bladder and prostate diseases such as interstitial cystitis; and non-bacterial chronic prostatitis (i.e. pelvic pain syndromes).
Urosphere has long-standing expertise in preclinical urology. Over the years we have developed a suite of preclinical models dedicated to all types of urinary incontinence, interstitial cystitis and overactive bladder.
Urosphere has established several partnerships with renowned institutions to developed and characterize new preclinical models in uro-oncology. Several projects are currently running related to bladder cancer and inflammation. For more information see our R&D section.
Our Services & Innovation
Urosphere’s experimental platform consists of both in vivo and in vitro pharmacological assays. We also provide access to a unique biobank of PDX preclinical models from urogenital cancers.
Finally, Urophere offers consultancy services for the preclinical development of your compounds.
Urosphere offers a range of services based on our innovative experimental models.
Development of customized models Codevelopment of therapeutic compounds Licensing.
Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation
Augé C. et al., 2022. Scandinavian Journal of Urology, 56 (4)
Augé C. et al., 2021. Frontiers in Pain Research, 2:642706
Characterization and Validation of a Chronic Model of Cyclophosphamide-Induced Interstitial Cystitis/Bladder Pain Syndrome in Rats
Augé C. et al., 2020. Frontiers in Pharmacology. 11:1305